Neoadjuvant Dato-DXd with durvalumab for high-risk, early stage HR+ /HER2- breast cancer achieved an overall pCR rate of 50%, with rates of 79% in the immune signature subtype [108] (Table 3). This evidence concerns the gene ERBB2 and breast cancer.